IN THE NEWS: Milestone Advisors Featured in Fierce Biotech on the Return of Biotech IPOs

Milestone Advisors Founder Matt Lane recently spoke with James Waldron of Fierce Biotech about the renewed momentum in biotech IPO activity and what the market is rewarding in 2026.

After a prolonged slowdown, investor sentiment in life sciences is beginning to shift. But the window is not wide open. Companies preparing to go public are being evaluated with discipline. Clear differentiation, thoughtful capital strategy, and credible communication matter more than ever.

As Matt noted, the companies succeeding in this environment are those that understand how to position their story for both specialist and returning generalist investors.

For management teams considering a public offering, preparation is not simply about timing. It is about ensuring strategy, narrative, and investor expectations are aligned well before launch.

Milestone Advisors works with private and public life sciences companies on IPO readiness, investor messaging, and capital markets strategy.

Read the full article in Fierce Biotech here.